Green Thumb Industries (GTII-CSE)

It has one of the strongest teams, some of the strongest assets and some of the strongest markets in the cannabis sector. The stock is recovering now with the underlying business continuing to grow. Some of the institutional managers could come back. It is possible for a glut in Cannabis in the U.S. as well as the one already in Canada but some states have limited licenses which is good for companies in those areas. Buy 22, Hold 0. Sell 0 (Analysts’ price target is $30.77)

Allan Tong’s Discover Picks GTII had a rough Q1 earlier this year as operating EBITDA margin slid to 28%, though it recovered to 31% in Q2. Q1 also saw a 6% slide in comparable sales as inflation corroded any gains. In Q2, though, revenues climbed 5% and stabilized. Q1 same-store sales fell 6%. To be fair, the market sell-off has been particularly unkind to cannabis stocks. Curaleaf is the better buy here, but in the ever-changing world of weed, GTII is worth keeping on your watch list. Read 3 Cannabis Stocks to go Higher for our full analysis.

The rare American cannabis stock, mostly in medical marijuana. They report Wednesday and he expects positive results. Be careful though, because cannabis stocks are way up now, overbought. If Biden wins, thought, it will be a tailwind for the US cannabis industry.